Neos Therapeutics Completes $20.6 Million Financing to Further Advance its Late-Stage ADHD Product Pipeline

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. ("Neos" or "the Company"), a specialty pharmaceutical company with a late-stage pipeline of innovative extended-release ("XR") products for Attention-Deficit Hyperactivity Disorder ("ADHD"), today announced that it has completed an oversubscribed round of financing, raising a total of $20.6 million. The financing included investments by Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, as well as other investors.

With the successful completion of this financing and the recent submission of a New Drug Application (NDA) for its methylphenidate XR-ODT drug candidate, NT-0102, an ADHD medication based on Neos' patented XR-ODT technology, the company is well positioned for growth.

Proceeds from this financing will support the Company's efforts during the FDA review of NT-0102 as well as the submission of NDAs for two additional ADHD drug candidates, an amphetamine XR-ODT and an amphetamine XR-Liquid Suspension.

Stimulant medications such as methylphenidate and amphetamine are effective in ameliorating the symptoms of ADHD, and extended-release formulations of these medications allow for once-daily dosing. However, recent data suggest that a significant percentage of children are unable to easily swallow solid dosage forms, and many remain uncomfortable doing so through adolescence. Neos' XR-ODT and XR-Liquid product candidates are designed to provide patient-friendly dosage forms for those who have difficulty swallowing or do not like to swallow intact tablets or capsules and may benefit from extended-release formulations.

"We are grateful to our investors for their continued confidence and support of the Company and our management team," commented Vipin K. Garg, Ph.D., President and CEO of Neos. "This places the Company in an excellent financial position as we prepare to transition to a commercial enterprise during the next six to twelve months."

About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended-release (XR) oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a generic of Tussionex® (hydrocodone and chlorpheniramine) extended-release oral suspension for the treatment of cough and upper respiratory symptoms of a cold. The Company's products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statement.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.